This research included study the relation between FGF21 and insulin resistance in hyperlipidaemia. The results demonstrated that the normal mean of FGF21 in serum control group was (69.4±2.9 pg/ml) and there was a significant increasing in FGF21 concentration in patients (108.05±4.03 pg/ml ) compared with control group, also the results showed a significant increase in the concentration of fasting glucose, insulin, homeostasis model for insulin resistance (HOMA-IR), Total cholesterol, Triglycerides, low density lipoprotein for cholesterol (LDL-C) and very low density lipoprotein for cholesterol (VLDL-C) and Malondialdehyde (MDA), while a significantly decrease had been shown in concentration of high density lipoprotein for cholesterol (HDL-C), adiponectin and Arylestase activity in hyperlipidemia patients compared with control group. Correlation coefficients of FGF21 hormone with these clinical parameters showed a positivly significant correlation with Glucose, insulin, HOMA-IR, Total cholesterol, Triglycerides, LDL-C, VLDL-C and MDA concentration, while FGF21 elucidated a significant negative correlation with HDL-C, arylesterase activity and adiponectin concentration. The conclusion of this study was that FGF21 concentration corelated significantly in hyperlipidemia with insulin resistance, and FGF21 high concentration can be represented as a biomarker in hyperlipidemia.